Sugi Predict

Sugi Predict / Compounds / SCHEMBL17583370

SCHEMBL17583370

SCHEMBL17583370

O=C(CC1CCNCC1)Nc1cncc(-c2ccc3[nH]nc(-c4nc5c(-c6cccc(F)c6)nccc5[nH]4)c3c2)c1

nearest known ligand 0.79

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 9/20 0.79
▸ CLK2 P49760 12/20 0.66
▸ CLK3 P49761 12/20 0.66
▸ DYRK1A Q13627 12/20 0.66
▸ CLK1 P49759 1/20 0.60
▸ GSK3B P49841 1/20 0.60
▸ DYRK2 Q92630 1/20 0.60
▸ CLK4 Q9HAZ1 1/20 0.60
▸ DYRK1B Q9Y463 1/20 0.60
▸ TGFBR1 P36897 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17555925 0.94 WNT1 (0.70) WNT1CLK2CLK3DYRK1ACLK1
SCHEMBL17583396 0.94 WNT1 (0.71) WNT1CLK2CLK3DYRK1ACLK1
SCHEMBL17588455 0.93 WNT1 (0.70) WNT1CLK2CLK3DYRK1A
SCHEMBL17588490 0.92 WNT1 (0.68) WNT1CLK2CLK3DYRK1A
SCHEMBL17588855 0.91 WNT1 (0.68) WNT1CLK2CLK3DYRK1ACLK1
SCHEMBL17556697 0.91 CLK2 (0.79) WNT1CLK2CLK3DYRK1ATGFBR1
SCHEMBL18450415 0.91 CLK2 (0.77) WNT1CLK2CLK3DYRK1ATGFBR1
SCHEMBL17588897 0.91 WNT1 (0.67) WNT1CLK2CLK3DYRK1ACLK1
SCHEMBL17588508 0.90 CLK2 (0.71) WNT1CLK2CLK3DYRK1A
SCHEMBL17593512 0.90 WNT1 (0.82) WNT1CLK2CLK3DYRK1ACLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10081631-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-09-25 — — US claimed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US claimed
US-9828372-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-11-28 — — US claimed
US-20170260179-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2017-09-14 — — US claimed
US-9475807-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-10-25 — — US claimed
WO-2016040182-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO claimed
US-10081631-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-09-25 — — US disclosed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US disclosed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US disclosed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US disclosed
US-9828372-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-11-28 — — US disclosed
US-9828372-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-11-28 — — US disclosed
US-9828372-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-11-28 — — US disclosed
US-20170260179-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2017-09-14 — — US disclosed
US-9475807-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-10-25 — — US disclosed
US-9475807-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-10-25 — — US disclosed
US-9475807-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-10-25 — — US disclosed
WO-2016040182-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO disclosed
US-20160075701-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-17 — — US disclosed
US-20160075701-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 803/4885CLK3 655/4885
US-20160075701-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 803/4885CLK3 655/4885
US-10081631-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A WNT1 1/4885CLK2 803/4885CLK3 655/4885
US-20170260179-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A WNT1 1/4885CLK2 803/4885CLK3 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.